Literature DB >> 33989619

Embelin-loaded chitosan gold nanoparticles interact synergistically with ciprofloxacin by inhibiting efflux pumps in multidrug-resistant Pseudomonas aeruginosa and Escherichia coli.

Tushar Khare1, Sneha Mahalunkar2, Varsha Shriram3, Suresh Gosavi4, Vinay Kumar5.   

Abstract

A global upsurge in emergence and spread of antibiotic resistance (ABR) in bacterial populations is a serious threat for human health. Unfortunately, ABR is no longer confined to nosocomial environments and is frequently reported from community microbes as well. The ABR is resulting in shrinking potent antibiotics pool and thus necessitating novel and alternative therapies and therapeutics. Current investigation was aimed to assess the synergistic potential of a synthesized, phytomolecule-loaded, polysaccharide-stabilized metallic nanoparticles (NPs) against Pseudomonas aeruginosa (PA) and Escherichia coli (EC) isolated from river waters. ABR profiling of these strains characterized them as multidrug resistant (MDR). Synthesized embelin (Emb, isolated from Embelia tsjeriam-cottam)-loaded, chitosan-gold (Emb-Chi-Au) NPs were assessed for their potential synergistic activity with ciprofloxacin (CIP) via checker-board assay and time-kill curve analysis. The NPs reduced the minimal inhibitory concentration (MIC) of CIP by 16- and 4-fold against MDR PA (PA-r) and EC (EC-r) strains, respectively. Fractional inhibitory concentration (FIC) indices with ≤0.5 values confirmed the synergy between the Emb-Chi-Au NPs and CIP, which was further confirmed at ½ MICs in both PA-r and EC-r via time-kill curve analysis. In order to decipher the mode of action, efflux pump inhibitory effects of Emb-Chi-Au NPs were evaluated in terms of the increase in the EtBr mediated fluorescence in control versus NP-treated MDR strains. Molecular docking based in silico simulations were used to predict the interactions between Emb and the active sites of the efflux pump related proteins in PA-r (MexA, MexB and OprM) and EC-r (AcrA, AcrB and TolC), which revealed the probable bond formation between Emb and respective amino acid residues.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibacterial resistance; Efflux pumps; Embelin; Molecular docking; Multidrug resistance; Nano-composites; Potentiation

Year:  2021        PMID: 33989619     DOI: 10.1016/j.envres.2021.111321

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  5 in total

1.  Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG.

Authors:  Yun-Dan Zheng; Tairan Zhong; Haiming Wu; Nan Li; Zuye Fang; Linlin Cao; Xing-Feng Yin; Qing-Yu He; Ruiguang Ge; Xuesong Sun
Journal:  Microbiol Spectr       Date:  2022-06-08

2.  Synthesis of Chitosan-Based Gold Nanoparticles: Antimicrobial and Wound-Healing Activities.

Authors:  Amr H Hashem; Amr M Shehabeldine; Omar M Ali; Salem S Salem
Journal:  Polymers (Basel)       Date:  2022-06-05       Impact factor: 4.967

Review 3.  Silver and Gold Nanoparticles for Antimicrobial Purposes against Multi-Drug Resistance Bacteria.

Authors:  Navid Rabiee; Sepideh Ahmadi; Omid Akhavan; Rafael Luque
Journal:  Materials (Basel)       Date:  2022-02-27       Impact factor: 3.623

4.  Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic.

Authors:  Amr Selim Abu Lila; Bader Huwaimel; Ahmed Alobaida; Talib Hussain; Zeeshan Rafi; Khalid Mehmood; Marwa H Abdallah; Turki Al Hagbani; Syed Mohd Danish Rizvi; Afrasim Moin; Abobakr F Ahmed
Journal:  Materials (Basel)       Date:  2022-08-18       Impact factor: 3.748

Review 5.  Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption.

Authors:  Nutthapoom Pathomthongtaweechai; Chatchai Muanprasat
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.